Evidence map›Paper›PMID 28449955›Full record

Trial reportJournal of substance abuse treatment2018

Predictors of induction onto extended-release naltrexone among unemployed heroin-dependent adults.

Brantley P Jarvis, August F Holtyn, Meredith S Berry, Shrinidhi Subramaniam, Annie Umbricht, Michael Fingerhood, George E Bigelow, Kenneth Silverman

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of substance abuse treatment, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Brantley P JarvisJohns Hopkins University School of Medicine, United States.
August F HoltynJohns Hopkins University School of Medicine, United States.
Meredith S BerryJohns Hopkins University School of Medicine, United States.
Shrinidhi SubramaniamJohns Hopkins University School of Medicine, United States.
Annie UmbrichtJohns Hopkins University School of Medicine, United States.
Michael FingerhoodJohns Hopkins University School of Medicine, United States.
George E BigelowJohns Hopkins University School of Medicine, United States.
Kenneth SilvermanJohns Hopkins University School of Medicine, United States. Electronic address: ksilverm@jhmi.edu.
Johns Hopkins University · US

Funding

HUMAN BEHAVIORAL PHARMACOLOGY OF SUBSTANCE ABUSET32DA007209 · NIDA · JOHNS HOPKINS UNIVERSITY · PI Eric C. Strain, Elise M Weerts · 1985 to 2026
$12.9M
Employment-Based Depot Naltrexone Clinical TrialR01DA019497 · NIDA · JOHNS HOPKINS UNIVERSITY · PI SILVERMAN, KENNETH · 2005 to 2016
$6.3M
NIDA NIH HHS R01 DA019497NIDA NIH HHS T32 DA007209
6 · The paper itself

Abstract

BACKGROUND AND

aimExtended-release naltrexone (XR-NTX) blocks the effects of opioids for 4weeks; however, starting treatment can be challenging because it requires 7 to 10days of abstinence from all opioids. In the present study we identified patient and treatment characteristics that were associated with successful induction onto XR-NTX.

methods144 unemployed heroin-dependent adults who had recently undergone opioid detoxification completed self-report measures and behavioral tasks before starting an outpatient XR-NTX induction procedure. Employment-based reinforcement was used to promote opioid abstinence and adherence to oral naltrexone during the induction. Participants were invited to attend a therapeutic workplace where they earned wages for completing jobs skills training. Participants who had used opioids recently were initially invited to attend the workplace for a 7-day washout period. Then those participants were required to provide opioid-negative urine samples and then take scheduled doses of oral naltrexone to work and earn wages. Participants who had not recently used opioids could begin oral naltrexone immediately. After stabilization on oral naltrexone, participants were eligible to receive XR-NTX and were randomized into one of four treatment groups, two of which were offered XR-NTX. Binary and multiple logistic regressions were used to identify characteristics at intake that were associated with successfully completing the XR-NTX induction.

results58.3% of participants completed the XR-NTX induction. Those who could begin oral naltrexone immediately were more likely to complete the induction than those who could not (79.5% vs. 25.0%). Of 15 characteristics, 2 were independently associated with XR-NTX induction success: legal status and recent opioid detoxification type. Participants who were not on parole or probation (vs. on parole or probation) were more likely to complete the induction (OR [95% CI]=2.5 [1.1-5.7], p=0.034), as were those who had come from a longer-term detoxification program (≥21days) (vs. a shorter-term [<21days]) (OR [95% CI]=7.0 [3.0-16.6], p<0.001).

conclusionsOur analyses suggest that individuals recently leaving longer-term opioid detoxification programs are more likely to complete XR-NTX induction. Individuals on parole or probation are less likely to complete XR-NTX induction and may need additional supports or modifications to induction procedures to be successful.

Indexed as

UnemploymentAdultDelayed-Action PreparationsFemaleHeroinHumansInjections, IntramuscularMaleNaltrexoneNarcotic AntagonistsOpioid-Related DisordersSubstance Abuse DetectionSubstance Abuse, IntravenousDelayed-Action PreparationsHeroinNaltrexoneNarcotic AntagonistsExtended-release naltrexoneHeroinInductionOpioids

Identifiers

PMID28449955
PMCPMC5650550
OpenAlexW2605517464

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.